INTRODUCTION
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that robs us of our most human qualities. Beyond its devastating effects on patients, AD is also a major burden for patients' families and implies enormous healthcare costs [1] . To date, no disease-modifying treatment is available, and therefore research on the molecular basis of AD must continue. The aggregation of the amyloid-beta peptide (Aβ) in the brain is strongly associated with AD [2] . Aβ is obtained from the transmembrane amyloid precursor protein (APP) through the sequential cleavage of β-and γ-secretase. γ-secretase cleavage is not specific, leading to Aβ peptides of different lengths, Aβ38 to Aβ43, ranging from 38 to 43 residues. Among them, Aβ42 is considered to be the peptide most strongly linked to AD, as levels of this variant are an indication of AD progression [3] , and several familial AD (fAD) mutations that give rise to early AD alter the Aβ40/Aβ42 ratio in favor of Aβ42 production [4] . Upon release from the membrane into the extracellular media, the Aβ peptide has a strong tendency to aggregate. This aggregation is a multistep process involving various aggregates that ultimately leads to the formation of amyloid fibrils. Due to the heterogeneity and transient nature of this process, the exact molecular form of Aβ responsible for the neurotoxicity observed in AD is not known. Therefore, characterizing Aβ aggregation is of utmost importance in the AD field. One of the techniques with the potential to characterize this process is nuclear magnetic resonance spectroscopy (NMR) [5] [6] [7] [8] [9] [10] [11] [12] , which requires the use of specific labels introduced through recombinant expression of Aβ.
A large number of strategies have been developed to produce recombinant Aβ42.
However, due to the aggregation-prone nature of Aβ42, initial approaches resulted in the production of modified Aβ42 sequences rather than of the wild type. Modifications included oxidation on the methionine 35 side chain of Aβ42 to methionine sulfoxide (Met-35(ox)Aβ42) [6, 13] , Aβ42 fused to a tag [14] [15] [16] , and Aβ42 containing unnatural mutations in its sequence [6, 17] or additional N-terminal residues [18] [19] [20] [21] . More recently, several strategies have led to the production of wild-type Aβ42 with satisfactory yields [22] [23] [24] [25] [26] [27] [28] , as well as isotopically labeled 15 N and 15 N, 13 C Aβ42 [29, 30] . One particularly attractive strategy initially proposed by Satakarni and Curtis relies on the expression of Aβ42 fused to Small Ubiquitin-like Modifier (SUMO) [27] .
They showed that SUMO solubilizes Aβ42, since the SUMO-Aβ42 fusion protein was obtained from both soluble and insoluble cell lysates. However, in spite of the solubilizing power shown by SUMO, Weber et al. have recently reported on a purification protocol to obtain 15 N and 15 N, 13 C Aβ42 starting from SUMO-Aβ42 accumulated in inclusion bodies, and thus used denaturing buffers for the lysis and initial purification steps [29] .
Working under denaturing conditions makes proteins more vulnerable to chemical modifications, leading, for example, to the oxidation of the methionine side chain to methionine sulfoxide. Aβ42 has a methionine in position . Indeed, there is much controversy in the literature regarding the role of Met-35(ox)Aβ42 in AD [31, 32] .
Therefore, in any Aβ42 purification strategy, it is critical to separate Met-35(ox)Aβ42 from Aβ42. Since these molecules differ in hydrophobicity, the most efficient method to separate them relies on the use of costly and time-consuming preparative reversed phase high performance liquid chromatography (RP-HPLC). Indeed, most Aβ42 purification protocols use this technique during the purification steps [22] [23] [24] [25] [26] [27] [28] [29, 30] .
In this paper, and inspired by the work of Satakarni and Curtis [27] , we exploit the capacity of SUMO to solubilize Aβ42 when these two molecules are fused and thus establish a new and efficient purification protocol. Rather than using highly denaturing conditions, our approach requires mild conditions for the lysis and initial immobilized metal affinity chromatography (IMAC) purification steps, which are followed by a desalting step, cleavage of Aβ42 from SUMO using the efficient SUMO protease 
MATERIALS AND METHODS

Reagents
The following labeled compounds were used: 15 
Cloning
The DNA encoding Aβ42 was synthesized by PCR with KOD polymerase (Novagen) methods and following the modular approach previously described [20] , but with the following primers to add the 15 bp on each side for the In-Fusion method: The amplified fragment was further purified and cloned into a pOPINS vector [33] previously cut with KpnI and HindIII (New England Biolabs) restriction enzymes using glucose. All cell cultures were also supplemented with 35 µg/mL chloramphenicol and 50 µg/mL kanamycin.
For [U- 15 N] Aβ42 expression, the following auto-induction procedure was applied, adapted from a previously described protocol [34] . Single colonies were picked and grown overnight in 2 x 12.5 mL LB, 1% glucose. The pre-cultures were centrifuged at 3,000 g for 10 min at 25ºC. Each pellet was transferred to 0.5 L 15 N-labeled P-5052
auto-inducing media with the appropriate antibiotics using a 3-L Erlenmeyer flask. The resulting cultures were grown for 6 h at 37ºC and 180 rpm. The temperature was then lowered to 25ºC, and the culture was incubated 22 h more at 180 rpm. The cells were then harvested by centrifugation at 9,000 g for 15 min at 4ºC and then frozen at -80°C. 
Protein purification
The cell pellet was resuspended in 6 mL buffer A per g of cells, supplemented with 1 EDTA-free Complete protease inhibitor pill (Roche) and 1 spatula of DNAse (Roche) per 50 mL of buffer. The resuspended cells were lysed using a cell disruptor (Constant Systems Ltd. U.K.) operating at 20,000 psi. The cell extract was then centrifuged at 30,000 g for 30 min at 4ºC, the supernatant filtered using a 0.45 µm and subsequently purified by IMAC. The supernatant was loaded at 1 mL/min onto a HisTrap HP 5-mL
Ni column (GE Healthcare), which was previously equilibrated with 5 column volumes of buffer A. After the loading step, the resin was washed with buffer B (300 mM NaCl, 50 mM sodium phosphate, 40 mM imidazole, 0.05% Tween-20 and 1 mM TCEP pH 8.0) for 10-15 column volumes, until UV absorbance was stable. The fusion protein was eluted at 2-5 mL/min using the following 3-step elution method: (a) a 15 mL linear gradient from 0 to 15% of buffer C (300 mM NaCl, 50 mM sodium phosphate, 500 mM imidazole, 0.05% Tween-20 and 1 mM TCEP pH 8.0), followed by (b) a 20 mL isocratic step at 15% buffer C and (c) a second isocratic step at 100% buffer C until UV absorbance was stable. IMAC fractions were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and those containing the fusion protein were pooled in batches of 10 mL. Subsequently, buffer was exchanged using a HiPrep 26/10 desalting column (GE Healthcare) equilibrated with 50 mM ammonium carbonate and 1 mM TCEP. Afterwards, the concentration and purity of protein was determined by nanodrop and RP-HPLC, respectively. Afterwards, to cleave Aβ42 from the SUMO fusion tag, samples were incubated overnight at 4ºC with SUMO protease (Ulp1) [33] in a 1:50 protease:protein ratio. The concentration of Aβ42 peptide after the cleavage was determined by RP-HPLC analysis. Subsequently, aliquots containing 3.75 mg Aβ42 were prepared and freeze-dried. Each of these aliquots was solubilized with 6.8 M guanidinium thiocyanate (GdnSCN) to 2.5 mg Aβ42/mL and sonicated for 5 min in an ice bath. Afterwards, the sample was further diluted with MilliQ water to 1.5 mg Aβ42/mL and 4 M GdnSCN, and centrifuged at 10,000 g for 6 min at 4ºC. Finally, 2.5 mL of the 1.5 mg Aβ42/mL was injected into a HiLoad Superdex 30 prep grade column (GE Healthcare), previously equilibrated with 50 mM ammonium carbonate, and eluted at 4ºC at a flow rate of 1 mL/min. The peaks corresponding to SUMO and monomeric Aβ42 were collected separately and their purity and concentration were determined by RP-HPLC. Both pools were freeze-dried, and the Aβ42 pool was subjected to the same GdnSCN solubilization protocol and SEC fractionation, as described. Pure Aβ42 was obtained after the two SEC steps. It was then aliquoted in the desired amounts, freezedried, and kept at -20ºC until use.
SDS-PAGE and WB
Samples for 60ºC. The concentration of monomeric Aβ42 was determined by RP-HPLC using the above-described conditions. A calibration curve was generated on the basis of an Aβ42 solution that had previously been quantified by amino acid analysis.
Mass spectrometry
The respectively, equipped with a cryogenic probe head. All data were processed and analyzed using TopSpin software from Bruker. Satakarni and Curtis previously reported on the capacity of SUMO to solubilize
RESULTS AND DISCUSSION
SUMO solubilizes Aβ42 when the two molecules are fused
Aβ42 when fused to it [27] . To examine this property under our expression conditions, we analyzed the supernatant corresponding to the soluble fraction, as well as the insoluble pellet resuspended in the same volume as that of the previously collected supernatant, by WB using 6E10, an antibody that recognizes residues 3 to 8 of the Aβ sequence ( Fig. 1) . Our results indicated that SUMO-Aβ42 was predominantly expressed in the soluble fraction. This finding contrasts with that described by Satakarni and
Curtis, who reported obtaining the same volumetric productivity of SUMO-Aβ42 after IMAC purification of the soluble supernatant and the insoluble pellet [27] . These differences can be explained by the fact that we produced SUMO-Aβ42 using minimal media while they used richer LB media. Given that protein expression yields are usually lower in the former media and that aggregation is highly dependent on protein concentration, it is likely that the concentrations of SUMO-Aβ42 produced in minimal media are not high enough to promote extensive aggregation and accumulation of the fusion protein in inclusion bodies. This explanation is supported by a report describing the expression and purification of the 50-amino acid protein medin [36] . Similar to 
Oxidation of methionine 35 is not observed during purification
Next, to design the purification strategy, we took into account various considerations. (Fig. 2) . This result supports the capacity of this method to detect the presence of Met-35(ox)Aβ42 in Aβ42 samples.
The first step of the purification relied on the (His) 6 tag present at the N-terminal of SUMO, which allowed a simple purification of SUMO-Aβ42 by IMAC using nondenaturing, degassed buffers in the presence of TCEP. Next, to cleave the SUMO-Aβ42 construct, the IMAC buffer was replaced by 50 mM ammonium carbonate and 1 mM TCEP at pH 9.0. This buffer allowed us to resolve the following two issues, namely to cleave Aβ42 from SUMO under basic pH-conditions reported to slow down Aβ42 aggregation [37] , and to subsequently lyophilize the sample, yielding a lyophilized powder free of insoluble salts. When present, the latter can promote Aβ42 aggregation upon subsequent resuspension. Under the 50 mM ammonium carbonate and 1 mM TCEP buffer, the cleavage of SUMO-Aβ42 using SUMO protease (Ulp1) [33] was highly effective, leading to SUMO and Aβ42, as analyzed by SDS-PAGE (Fig. 3A) and RP-HPLC (Fig. 3C) . The two bands detected in the SDS-PAGE analysis of SUMO-Aβ42 (Fig. 3A, lane 1) were assigned to two populations of SUMO-Aβ42 caused by either an incomplete denaturation of SUMO-Aβ42 prior to sample separation or subsequent partial renaturation during the separation. Products of incomplete translation during synthesis, and/or partial degradation during lysis, and/or sample processing of both SUMO and Aβ42 moieties were excluded as these would be evident in both the SDS-PAGE gels and the RP-HPLC profiles of the downstream SUMO protease-cleaved products ( Fig. 3A and 3C ).
Since the molecular weight of SUMO (12.4 kDa) is almost three-fold larger than that of Aβ42 (4.5 kDa), we proceeded with their separation by means of SEC (Fig. 3B) . To obtain the best yield for monomeric Aβ42, it was critical to ensure the absence of Aβ42 aggregates at the time of injection. To this end, we resuspended the lyophilized powder obtained after SUMO protease cleavage at 2.5 mg/mL Aβ42 in 6.8 M GdnSCN. This strong chaotropic reagent is able to solubilize plaque cores from the brains of AD patients [2] . Therefore, performing this step ensured complete solubilization of the sample containing Aβ42 and SUMO. To minimize Aβ42 aggregation during elution from the column, SEC was performed at 4ºC. At this temperature, 6.8 M GdnSCN precipitates. To avoid this, the sample containing Aβ42 and SUMO was diluted to 4 M GdnSCN and 1.5 mg/mL Aβ42 before subjecting it into the SEC apparatus. To prevent the oxidation of Met-35, SEC was carried out using carefully degassed 50 mM ammonium carbonate at pH 9.0. Again, we chose this buffer because its basic pH has been reported to minimize Aβ42 aggregation [37] and because its volatility allowed subsequent lyophilization of the fractions containing Aβ42 without leaving any insoluble salts in the lyophilized powder. To completely separate Aβ42 from SUMO, a second SEC purification was required (Fig. 3B) . After this second SEC, the purity of the peptide and the absence of Met-35(ox)Aβ42 (compare to Fig. 2A ) was confirmed by RP-HPLC (Fig. 3C ). This expression and purification strategy allowed us to obtain 6 mg [U-15 N] Aβ42 and 2 mg [U-2 H, 13 C, 15 N] Aβ42 per L of culture. The purity of labeled peptides was determined by RP-HPLC and found to be > 98% (Fig. 4A) . Moreover, their identity and label incorporation was determined by HRMS analysis (Fig. 4B ) and reported in Table 1 . (Fig. 5B ). This buffer has been reported to disaggregate Aβ into its constituent monomers while preserving hydrogen deuterium exchange (HDX) information [6, [38] [39] [40] [41] [42] . HDX experiments are among the techniques most used in the literature to obtain structural information about amyloid fibrils [6, 38, 39, 41] and also about aggregates formed during fibril formation [42] . Under these conditions, we observed at least 37-38 N-H cross-peaks corresponding to the amides of the Aβ42 backbone. Among them, six peaks appeared at the characteristic chemical shifts of glycines, consistent with the six glycines present in the Aβ42 sequence. Moreover, we expect that the [U-2 H, 13 C, 15 N] Aβ42 sample will pave the way for NMR studies of Aβ42 in the form of high molecular weight complexes, including those formed in a membrane environment.
The labeled Aβ42 is amenable to NMR-based structural studies
Conclusions
We have produced [U- (https://www.rpeptide.com/products/labeled-peptides-and-proteins/beta-amyloidlabeled-peptides-recombinant/). The SUMO protease used in this study was prepared inhouse, the methodology is very simple and can be performed by any lab wishing to produce large quantities of the enzyme to reduce costs [43] . SUMO protease is also available commercially as 100,000 U for €600 (less than one cent per unit) and, as we estimate that 5,000-10,000 U should be sufficient to cut 25mg of the SUMO-Aß42 fusion overnight, this digestion step should not therefore be seen as prohibitively expensive. Additionally, even in the case that a laboratory would need to invest in the required FPLC columns-we assume possession of an FPLC system-the cost of the columns would be recovered in the first Aβ42 purification, and the columns themselves, especially Superdex 30, can be used for many other purifications. Therefore, the expression and purification protocol described herein offers an alternative inexpensive approach to previously described methods to obtain [U-15 N] Aβ42 [29, 30] and the first method to achieve [U-2 H, 13 
